Page 104 - Read Online

Page 8 of 10 Dolan et al. Mini-invasive Surg 2020;4:40 I http://dx.doi.org/10.20517/2574-1225.2020.17

This indicates to us that, by performing more cases of locally advanced NSCLC in a minimally invasive
manner, we can help patients proceed more quickly to indicated therapy.

While further work is needed to elucidate the appropriate management of locally advanced NSCLC, in
terms of neoadjuvant and adjuvant treatment, the minimally invasive surgical approach to this condition
has now come into its own. With perioperative, operative, and long-term outcomes now equivalent or
better than open thoracotomy, we recommend that experienced surgeons offer minimally invasive VATS
approach as the primary surgical method for locally advanced NSCLC.

DECLARATIONS
Authors’ contributions
Made substantial contributions to conception and design of the study and performed data analysis and
interpretation: Dolan DP, Dezube AR, Swanson SJ

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Dr. Swanson is a consultant for Covidien and Ethicon. Remaining authors declared that there are no
conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Eberhardt WEE, De Ruysscher D, Weder W, Le Pechoux C, De Leyn P, et al. 2nd ESMO consensus conference in lung cancer: locally
advanced stage III non-small-cell lung cancer. Ann Oncol 2015;26:1573-88.
2. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, et al. The IASLC lung cancer staging project: proposals for revision of
the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Onc 2016;11:39-51.
3. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest 2017;151:193-203.
4. Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, et al. NCCN guidelines: non-small cell lung cancer version 1.2020. J Natl
Compr Canc Netw 2019;17:1464-72.
5. De Leyn P, Dooms C, Kudzal J, Lardinois D, Passlick B. Revised ESTS Guidelines for preoperative mediastinal lymph node staging for
non-small-cell lung cancer. Euro J Cardiothorac Surg 2014;41-12.
6. Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, et al. Risk factors for occult mediastinal metastases in clinical stage I non-small cell
lung cancer. Ann Thorac Surg 2007;84:177-81.
7. Lyu L, Liu Y, Wang XY, Zhang, ZK, Tao, XL, et al. Potential value of FDG PET-CT in predicting occult lymph node metastasis in clinical
stage IA lung adenocarcinoma. Zhonghua Zhongliu Zazhi 2019;41:441-7. (in Chinese)
8. Lin JT, Yang XN, Zhong WZ, Liao RQ, Dong S, et al. Association of maximum standardized uptake value with occult mediastinal lymph
node metastases in cN0 non-small cell lung cancer. Eur J Cardiothorac Surg 2016;50:914-9.
9. Mizuno T, Arimura T, Kuroda H, Sakakura N, Yatabe Y, et al. Histological type predicts mediastinal metastasis and surgical outcome in
resected cN1 non-small cell lung cancer. Gen Thorac Cardiovasc Surg 2017;65:519-26.
10. Bezjak A, Temin S, Franklin G, Giaccone G, Govindan R, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell